Evidence map›Paper›PMID 23290730›Full record

ReviewThe Medical clinics of North America2013

Obesity and diabetic kidney disease.

Christine Maric-Bilkan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Medical clinics of North America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 2 pooled it
11.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 167 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Short-term changes after a weight reduction intervention in advanced diabetic nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2013
    Trial
  5. Article
  6. Review
  7. Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Christine Maric-BilkanDepartment of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216-4505, USA. cmaric@umc.edu
University of Mississippi Medical Center · US

Funding

ESTROGEN AND INFLAMMATION IN DIABETIC NEPHROPATHYR01DK075832 · NIDDK · UNIVERSITY OF MISSISSIPPI MED CTR · PI MARIC-BILKAN, CHRISTINE · 2007 to 2011
$1.4M
NIDDK NIH HHS R01 DK075832NIDDK NIH HHS R01DK075832
6 · The paper itself

Abstract

Obesity and diabetes are major causes of CKD and ESRD, and are thus enormous health concerns worldwide. Both obesity and diabetes, along with other elements of the metabolic syndrome including hypertension, are highly interrelated and contribute to the development and progression of renal disease. Studies show that multiple factors act in concert to initially cause renal vasodilation, glomerular hyperfiltration, and albuminuria, leading to the development of glomerulopathy. The coexistence of hypertension contributes to the disease progression, which, if not treated, may lead to ESRD. Although early intervention and management of body weight, hyperglycemia, and hypertension are imperative, novel therapeutic approaches are also necessary to reduce the high morbidity and mortality associated with both obesity-related and diabetes-related renal disease.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesObesityAdiponectinAnimalsCytokinesDisease ProgressionEarly Medical InterventionGlomerular Filtration RateHumansKidneyKidney Failure, ChronicLeptinMedication Therapy ManagementMiceAdiponectinCytokinesLeptin

Identifiers

PMID23290730
PMCPMC3539140
OpenAlexW2070447089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.